Array BioPharma and Genentech have expanded their relationship in oncology by forming a second collaboration to develop both company’s small molecule checkpoint kinase 1 (ChK-1) programmes, which include Genentech’s Phase 1 GDC-0425 and Array’s preclinical-stage ARRY-575. Genentech will be responsible for all clinical development and commercialisation activities. In return, Array will receive US$28 M upfront, potential clinical and commercial milestones of up to US$685 M and double-digit royalties. The two companies first partnered in 2003 for the development and commercialisation of the pan-Akt inhibitor GDC-0068, which entered clinical development in 2010.